Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight cancer. Checkpoint inhibitors like nivolumab and pembrolizumab have shown remarkable efficacy in treating cancers such as melanoma and non-small cell lung cancer. However, not all patients respond to immunotherapy, and research is ongoing to identify predictive biomarkers.
